Results 31 to 40 of about 6,465,161 (268)

Progression-free survival between the Collatamp group and the control group.

, 2022
There was no significant difference in the estimated 2-year progression-free survival rate between the two groups (log-rank p-value = 0.092).
Jaeim Lee (11204526), Seong Taek Oh (10208648), Youn Young Park (10208645), Kil-yong Lee (6050867)   +3 more
core   +1 more source

Venetoclax‐Based Therapy as a Bridge to Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Pediatric Acute Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Relapsed and/or refractory (R/R) pediatric acute leukemia carries a dismal prognosis, largely driven by chemoresistance to conventional salvage therapy. The BH3‐mimetic venetoclax, combined with chemotherapy or hypomethylating agents, has demonstrated efficacy in small clinical trials.
Katherine S. Colman, Deborah Meyran, Vajiranee Malalasekera, Heather Weerdenburg, Janine Campbell, Rachel Conyers, Stacie Wang, Hannah Walker, Seong Lin Khaw, Diane Hanna   +9 more
wiley   +1 more source

Exploring the effects of doxorubicin on survival rates in glioma patients: a comprehensive systematic review

European Journal of Medical Research
Background Glioma is still one of the most aggressive and common types of brain and central nervous system cancer, with few effective treatment options.
Elyar Mahboubi, Mahdieh Mondanizadeh, Amir Almasi-Hashiani, Elham Ghasemi   +3 more
doaj   +1 more source

Progression-free survival versus post-progression survival and overall survival in WHO grade 2 gliomas

Acta Oncologica
Background and purpose: Progression-free survival (PFS) remains to be validated as an outcome measure for diffuse WHO grade 2 gliomas, and knowledge about the relationships between PFS, post-progression survival (PPS), and overall survival (OS) in this ...
Lisa Millgård Sagberg, Øyvind Salvesen, Asgeir Store Jakola, Erik Thurin, Eddie de Dios, Noah L.A. Nawabi, John L. Kilgallon, Joshua D. Bernstock, Vasileios K. Kavouridis, Timothy R. Smith, Ole Solheim   +10 more
doaj   +1 more source

Progression-free survival by the dose of the regorafenib

, 2016
Progression-free survival by the dose of the ...
Oriana Nanni (16186), Helen Charamis (3592043), Khashayar Esfahani (3592046), Emanuela Scarpi (382324), Lawrence C. Panasci (3592037), Cristiano Ferrario (3592034), Ivan Strepponi (2452123), Wilson H. Miller Jr (504574), Adrian Langleben (3592040)   +8 more
core   +1 more source

Chemotherapy for Spinal Cord Intramedullary Pediatric Low‐Grade Glioma—A Systematic Literature Review

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric intramedullary low‐grade gliomas (PIMLGGs) are rare neoplasms that present unique clinical and management challenges. Although surgery remains the primary tool for tissue diagnosis and decompression, complete gross‐total resection is frequently unfeasible due to the infiltrative nature of these lesions.
Olga M. Sergeenko, Segev Gabay, Jonathan Roth, Amit Ringel, Rina Dvir, Shlomi Constantini   +5 more
wiley   +1 more source

Impact of diagnosis to treatment interval on outcomes in patients with newly diagnosed marginal zone lymphoma - a US multisite study

Experimental Hematology & Oncology
Diagnosis-to-treatment interval (DTI) is an important prognostic factor in patients with newly diagnosed aggressive lymphomas, however the impact of DTI on outcomes in marginal zone lymphoma (MZL) is unknown.
Narendranath Epperla, Geoffrey Shouse, Natalie S. Grover, Pallawi Torka, Kaitlin Annunzio, Marcus Watkins, Andrea Anampa-Guzmán, Beth Christian, Colin Thomas, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Reem Karmali, Nancy L. Bartlett, Adam J. Olszewski   +13 more
doaj   +1 more source

Time-to-progression, time-to-local progression, progression-free-survival and overall survival after TACE among groups.

, 2018
Time-to-progression, time-to-local progression, progression-free-survival and overall survival after TACE among groups.
Han Chu Lee (154230), Danbi Lee (3682918), Yung Sang Lee (481493), Jihyun An (2232697), Young-Hwa Chung (129517), Seong Kyun Na (5349014), Yong Moon Shin (4164724), Gwang Hyeon Choi (5349011), Ju Hyun Shim (481492), Kang Mo Kim (154235), Young-Suk Lim (388118)   +10 more
core   +1 more source

Abatacept for Prophylaxis of Acute and Chronic Graft‐Versus‐Host‐Disease in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation—A Systematic Review and Meta‐Analysis of Cohort Studies

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Graft‐versus‐host disease (GvHD) remains one of the most significant complications of hematopoietic stem cell transplantation (HSCT). Abatacept, a selective T‐cell costimulation modulator, is a relatively novel prophylactic agent, though pediatric data remain limited.
Matthijs D. Kruizinga, Anne B. Verbeek, Caroline A. Lindemans, Emilie P. Buddingh   +3 more
wiley   +1 more source

Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study

Cancer Management and Research, 2014
Yiyun Tang,1 Paul Bycott,1 Örjan Åkerborg,2 Linus Jönsson,2 Sylvie Negrier,3 Connie Chen4 1Pfizer Global Research and Development, La Jolla, CA, USA; 2OptumInsight, Stockholm, Sweden; 3Medical Oncology Department, University of Lyon, Lyon,
Tang Y, Bycott P, Åkerborg Ö, Jönsson L, Negrier S, Chen C   +5 more
doaj